Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients

Journal of Antimicrobial Chemotherapy

Volumn 55, Issue 3, 2005, Pages 352-361

  Wenzel, R ^a   Del Favero, A ^b   Kibbler, C ^c   Rogers, T ^d   Rotstein, C ^e   Mauskopf, J ^f   Morris, S ^g   Schlamm, H ^h   Troke, P ⁱ   Marciniak, A ⁱ  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PERUGIA   (Italy)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

^e HAMILTON HEALTH SCIENCES   (Canada)

^f RTI HEALTH SOLUTIONS   (United States)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

^h PFIZER INC   (United States)

ⁱ PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Cost effectiveness; Model; RCT; Sensitivity analyses

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CHLORPHENIRAMINE; FLUCYTOSINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROCORTISONE; ITRACONAZOLE; PARACETAMOL; PETHIDINE; PIPERACILLIN PLUS TAZOBACTAM; VORICONAZOLE;

ARTICLE; ASPERGILLOSIS; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; ECONOMIC EVALUATION; HEALTH CARE SYSTEM; HUMAN; IMMUNE DEFICIENCY; INTENSIVE CARE UNIT; LENGTH OF STAY; LIVER TOXICITY; NEPHROTOXICITY; NEUTROPENIA; RESOURCE ALLOCATION; SENSITIVITY ANALYSIS; SURVIVAL; TREATMENT OUTCOME;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLOSIS; COST SAVINGS; COST-BENEFIT ANALYSIS; DEOXYCHOLIC ACID; DRUG COMBINATIONS; HEALTH CARE COSTS; HUMANS; IMMUNOCOMPROMISED HOST; PYRIMIDINES; TRIAZOLES;

EID: 20144370277     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh535     Document Type: Article

References (35)

1. Kontoyiannis, D. P & Bodey, G. P. (2002). Invasive aspergillosis in 2002: an update. European Journal of Clinical Microbiology and Infectious Diseases 21, 161-72.
2. Groll, A. H. & Walsh, T. J. (2001). Uncommon opportunistic fungi: new nosocomial threats. European Journal of Clinical Microbiology and Infectious Diseases 7, Suppl. 2, 8-24.
3. Pinner, R. W., Teutsch, S. M., Simonsen, L. et al. (1996). Trends in infectious diseases mortality in the United States. Journal of the American Medical Association 275, 189-93.
4. McNeil, M. M., Nash, S. L., Hajjeh, R. A. et al. (2001). Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clinical Infectious Diseases 33, 641-7.
5. Garber, G. (2001). An overview of fungal infections. Drugs 61, Suppl. 1, 1-12.
6. Lin, S.-J., Schranz, J. & Teutsch, S. M. (2001). Aspergillosis case-fatality rate: systematic review of the literature. Clinical Infectious Diseases 32, 358-66.
7. Briegel, J., Forst, H., Spill, B. et al. (1995). Risk factors for systemic fungal infections in liver transplant recipients. European Journal of Clinical Microbiology and Infectious Diseases 14, 375-82.
8. Rabkin, J. M., Oroloff, S. L., Corless, C. L. et al. (2000). Association of fungal infection and increased mortality in liver transplant recipients. American Journal of Surgery 179, 426-30.
9. Pannuti, C., Gingrich, R., Pfaller, M. A. et al. (1992). Nosocomial pneumonia in patients having bone marrow transplants. Attributable mortality and risk factors. Cancer 69, 2653-62.
10. Wilson, L. S., Reyes, C. M., Stolpman, M. et al. (2002). The direct cost and incidence of systemic fungal infections. Value in Health 5, 26-34.
11. Dasbach, E. J., Davies, G. M. & Teutsch, S. M. (2000). Burden of aspergillosis-related hospitalizations in the United States. Clinical Infectious Diseases 31, 1524-8.
12. Dismukes, W. E. (2000). Introduction to antifungal drugs. Clinical Infectious Diseases 30, 653-7.
13. Stevens, D. A., Kan, V. L., Judson, M. A. et al. (2000). Practice guidelines for diseases caused by Aspergillus. Clinical Infectious Diseases 30, 696-709.
14. Patterson, T. F., Kirkpatrick, W. R., White, M. et al. (2000). Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. Medicine (Baltimore) 79, 250-60.
15. Denning, D. W. (1998). Invasive aspergillosis. Clinical Infectious Diseases 26, 781-803.
16. Al-Mohsen, I. & Hughes, W. T. (1998). Systemic antifungal therapy: past, present and future. Annals of Saudi Medicine 18 28-38.
17. Sheppard, D. & Lampiris, H. W (1998). Antifungal agents. In Basic & Clinical Pharmacology (Katzung, B. G., Ed.), pp. 780-7. Appleton & Lange, Stamford, CT, USA.
18. Wingard, J. R., White, M. H., Anaissie, E. et al. (2000). A randomised, double-blind comparative trial evaluating the safety of liposomal Amphotericin B versus Amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clinical Infectious Diseases 31, 1155-63.
19. Bowden, R., Chandrasekar, P., White, M. H. et al. (2002). A double-blind, randomised, controlled trial of Amphotericin B colloidal dispersion versus Amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clinical Infectious Diseases 35, 359-66.
20. Facts and Comparisons. (2001). Antifungal agents. In Drug Facts and Comparisons, pp. 1359-64. Facts and Comparisons, St. Louis, MO, USA.
21. Herbrecht, R., Denning, D. W., Patterson, T. F. et al. (2002). Voriconazole versus Amphotericin B for primary therapy of invasive aspergillosis. New England Journal of Medicine 347, 408-15.
22. Bowling, A. Ed. (1997). Consensus Methods in Research Methods in Health. Open University Press, Buckingham, UK.
23. Cardinale, V. Ed. (2002). Red Book. Thomson Healthcare, Montvale, NJ, USA.
24. Resource-Based Relative-Value Scale (RBRVS). (2002). St Anthony Publishing/Medicode Publication, Salt Lake City, UT, USA.
25. Cagnoni, P., Walsh, T., Prendergast, T. et al. (2000). Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. Journal of Clinical Oncology 18, 2476-83.
26. Annemans, L., Moeremans, K. & van Gool, R. (2000). Economic evaluation of itraconazole in the empirical management of systemic fungal disease: a pan-European comparison. Poster presented at the European Haematology Association Conference, Birmingham, UK, June 25-28.
27. Flynn, T. N., Kelsey, S. M., Hazel, D. L. et al. (1999). Cost-effectiveness of amphotericin B plus G-CSF compared with amphotericin B monotherapy: treatment of presumed deep-seated fungal infection in neutropenic patients in the UK. Pharmacoeconomics 16, 543-50.
28. Persson, U., Tennvall, G. R., Andersson, S. et al. (1992). Cost-effectiveness analysis of treatment with liposomal amphotericin B versus conventional amphotericin B in organ or bone marrow transplant recipients with systemic mycoses. Pharmacoeconomics 2 500-8.
29. Dranitsaris, G., Phillips, P., Rotstein, C. et al. (1998). Economic analysis of fluconazole versus amphotericin B for the treatment of candidemia in non-neutropenic patients. Pharmacoeconomics 13, 509-18.
30. Ascioglu, S., Rex, J. H., de Pauw, B. et al. (2002). Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and haematopoietic stem cell transplants: an international consensus. Clinical Infectious Diseases 34, 7-14.
31. Gallis, H. A., Drew, R. H. & Pickard, W. W. (1990). Amphotericin B: 30 years of clinical experience. Review of Infectious Diseases 12, 308-29.
32. Kaltenbach, B. L. & Ross, M. B. (1998). Review of the lipid-based amphotericin B products. Pharmacy and Therapeutics 23, 487-94.
33. Walsh, T. J., Pappas, P., Winston, D. J. et al. (2002). Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. New England Journal of Medicine 346, 225-34.
34. Anon. (2002). MEDTAP Database of International Unit Costs for Economic Evaluations in Health Care. MEDTAP International, Bethesda, USA.
35. Veenstra, D. L., Saint, S. & Sullivan, S. D. (1999). Cost effectiveness of antiseptic-impregnated central venous catheters for the prevention of catheter-related bloodstream infection. Journal of the American Medical Association 282, 554-60.